摘要
Background Management of premature ventricular contractions （PVCs） and bradycardia is difficult, because most antiarrhythmic drugs may lead to more severe bradycardia, so other effective drugs with less side effects are alternatives for treating those patients. To evaluate the efficacy and safety of the traditional Chinese medicine Shensong Yangxin capsule （SYC） in patients with bradycardia and PVCs, a pilot study was conducted. Methods One hundred and sixty-eight patients with bradycardia and PVCs were randomly assigned to receive either SYC （trial group, = 86） or placebo （control group, = 82） for 4 weeks. ECG, 24-hour continuous ECG recording, echocardiography, quality of life, hepatic function and renal were evaluated at baseline and after 4-week treatment. Results The average heart rate, the fastest heart rate, and the lowest heart rate in the trial group were all significantly higher than those in the baseline and the control group after 4-week follow-up （ 〈 0.01, 0.05, 0.05, respectively.）. Compared with pretreatment, the PVCs in the trial group decreased significantly after treatment （1911.7 ±402.6 vs. 5550.1 ± 973.7, 〈 0.01）. Both the quality of life and the symptom scores in the trial group were significantly better than those in the control group. No severe adverse effects were reported. Conclusion SYC is effective and safe for the treatment of PVCs and bradycardia and improves the symptoms and quality of life.
Background Management of premature ventricular contractions （PVCs） and bradycardia is difficult, because most antiarrhythmic drugs may lead to more severe bradycardia, so other effective drugs with less side effects are alternatives for treating those patients. To evaluate the efficacy and safety of the traditional Chinese medicine Shensong Yangxin capsule （SYC） in patients with bradycardia and PVCs, a pilot study was conducted. Methods One hundred and sixty-eight patients with bradycardia and PVCs were randomly assigned to receive either SYC （trial group, = 86） or placebo （control group, = 82） for 4 weeks. ECG, 24-hour continuous ECG recording, echocardiography, quality of life, hepatic function and renal were evaluated at baseline and after 4-week treatment. Results The average heart rate, the fastest heart rate, and the lowest heart rate in the trial group were all significantly higher than those in the baseline and the control group after 4-week follow-up （ 〈 0.01, 0.05, 0.05, respectively.）. Compared with pretreatment, the PVCs in the trial group decreased significantly after treatment （1911.7 ±402.6 vs. 5550.1 ± 973.7, 〈 0.01）. Both the quality of life and the symptom scores in the trial group were significantly better than those in the control group. No severe adverse effects were reported. Conclusion SYC is effective and safe for the treatment of PVCs and bradycardia and improves the symptoms and quality of life.
基金
supported by Science and Technology Key Foundation of Guangdong Province(No.2010B031600166)
the Science and Technology Foundation of Guangdong Province(No.2011B061300072)
the Medical Scientific Research Foundation of Guangdong Province(No.A2014005)
